The First Approved CGRP Receptor Antagonist Nasal Spray for the Treatment of Migraine

zavegepant

CGRP receptor antagonist, first nasal spray FDA-approved for acute migraines in adults rational design based on known CGRP antagonists FDA approval, March 10, 2023 Bristol Myers Squibb, NY / Pfizer, Inc., NY

Drug Hunter Team

zavegepant, CGRP receptor antagonist, first nasal spray, FDA-approved for acute migraines in adults, rational design based on known CGRP antagonists, FDA approval, March 10, 2023, BRISTOL MYERS SQUIBB, NY / PFIZER, INC., NY

The First Approved CGRP Receptor Antagonist Nasal Spray for the Treatment of Migraine

zavegepant

Other molecules you may be interested in